Epirus Biopharmaceuticals

Epirus Biopharmaceuticals

closed

Expert insights on pharmaceuticals and health supplements to enhance mental and physical well-being.

HQ location
Massachusetts, United States
Launch date
Employees
Market cap
$15.7k
Enterprise value
($6m)
Share price
0.00 EPRSQ
Recent deals
  • Edit
Get premium to view all results
DateInvestorsAmountRound
-investor

€0.0

round
N/A

€0.0

round
investor investor

€0.0

round
investor investor

€0.0

round
investor investor investor investor investor investor investor investor

€0.0

round
*
N/A

$44.2m

Post IPO Equity
Total Funding000k
More about Epirus Biopharmaceuticals
Made with AI
Edit

Epirus Biopharma is dedicated to providing comprehensive information on pharmaceuticals and health supplements aimed at improving mental and physical health. The company focuses on educating consumers about the benefits and informed use of these products, particularly in relation to thyroid health and its impact on overall well-being. Epirus Biopharma operates in the health and wellness market, targeting individuals seeking to enhance their quality of life through informed health choices. The business model revolves around content creation and dissemination, leveraging the latest research and trends in the health industry to attract and retain a dedicated audience. Revenue is generated through advertising, partnerships, and possibly affiliate marketing with health supplement providers.

Keywords: pharmaceuticals, health supplements, thyroid health, mental well-being, physical well-being, consumer education, health industry, content creation, advertising, partnerships.

Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.
Book a Demo

Investments by Epirus Biopharmaceuticals

Edit
Bioceros
ACQUISITION by Epirus Biopharmaceuticals Sep 2015
Zalicus
ACQUISITION by Epirus Biopharmaceuticals Jul 2014